Blood-based biomarkers have the potential to revolutionize clinical practice and clinical trials in Alzheimer disease (AD). However, to date, this “holy grail” opportunity has not been realized owing to a broad range of issues, including the lack of a clearly defined context of use (COU), lack of standardization of methods, and numerous failures at replication. Recently, however, a shift in the paradigm has occurred, with my colleagues and I proposing specific COUs for blood-based biomarkers along with potential paradigms for advancing from discovery to clinic and potential acceptable standards.1,2
Now accepting applications for the Population Neuroscience of Alzheimer’s Disease and Age-related Dementia (PNA) T32 Training Grant
University of Pittsburgh, Graduate School of Public Health and Department of Psychiatry Now accepting applications for the Population Neuroscience of Alzheimer’s Disease and Age-related Dementia (PNA) T32 Training Grant Now accepting applications for pre-and...
